Clinical Investigation of Cardioprotective Effect of Early Administration of Sodium-glucose Cotransport-2 Inhibitors in Patients With Acute Myocardial Infarction

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study aims to investigate the effect of early administration of DAPA during ischemia and before pPCI on infarct size, reperfusion injury-related myocardial damage, cardioprotection from HF, and renoprotection from AKI in patients with AMI.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Patients with ST-elevation myocardial infarction (STEMI).

• STEMI was defined according to the Fourth Universal Definition of AMI.

• 18 - 80 years of age.

• Diabetics or non-diabetics.

• eGFR \> 45 ml/min/1.73m2.

• Blood pressure before first drug dosing \>110/70 mmHg.

Locations
Other Locations
Egypt
Mohammad Soliman
RECRUITING
Shibīn Al Kawm
Contact Information
Primary
Mohammad Soliman
dr.mhtantawy@gmail.com
+201003474565
Time Frame
Start Date: 2023-10
Estimated Completion Date: 2026-08
Participants
Target number of participants: 80
Treatments
Active_comparator: Dapagliflozin group
patients with MI will be treated with DAPA 10 mg once daily for three months.
Placebo_comparator: Placebo group
patients with MI will be treated with a matching placebo once daily for three months.
Related Therapeutic Areas
Sponsors
Leads: Mohammad Hussien Tantawy Soliman

This content was sourced from clinicaltrials.gov